应用2022年ACR/EULAR分类标准对既往诊断GPA患者再分类
本研究将2022年ACR/EULAR提出的肉芽肿性多血管炎(GPA)分类标准应用于65例既往已诊断GPA的韩国患者,其中48例(73.8%)可再分类为GPA,17例未分类为GPA者中16例再分类为显微镜下多血管炎(MPA)、1例为不可分类血管炎,且94.1%携带MPO-ANCA(或核周型(P)-ANCA)。
要点
- 65例既往诊断GPA患者中48例(73.8%)符合2022年ACR/EULAR分类标准。
- 未分类为GPA的17例中16例再分类为MPA、1例为不可分类血管炎。
- 未分类为GPA者中94.1%携带MPO-ANCA(或核周型(P)-ANCA)。
核心结论
- 2022年ACR/EULAR GPA分类标准与既往标准在既往诊断GPA患者中的一致率为73.8%。
- 作者认为2022年ACR/EULAR标准虽为最先进方法学流程的产物,但应注意其存在扭曲CHCC定义的一些后果,尤其需要进一步讨论条目权重。
研究设计与样本
- 本研究纳入65例符合2012年修订版国际Chapel Hill共识会议血管炎命名(CHCC)和2007年欧洲药品管理局GPA算法的GPA患者,并基于2022年ACR/EULAR标准进行再分类。
主要发现
- 65例患者中48例(73.8%)再分类为GPA。
- 17例未分类为GPA的患者中,16例再分类为MPA、1例为不可分类血管炎。
- 未分类为GPA的17例患者中94.1%携带MPO-ANCA(或核周型(P)-ANCA)。
- 若患者虽有活检肉芽肿或明确的GPA替代标志物但总分未达5分,则不能再分类为GPA。
关键数值与推荐
- 2022年ACR/EULAR GPA分类标准要求总分达到5分。
- 既往GPA诊断依据为2012年修订版CHCC命名和2007年欧洲药品管理局GPA算法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study applied the 2022 criteria for granulomatosis with polyangiitis (GPA) proposed by the ACR and EULAR (the 2022 ACR/EULAR criteria) to Korean patients with previously diagnosed GPA to investigate the number of patients who could be reclassified as having GPA. METHODS: Sixty-five patients with GPA, who met the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides and the 2007 European Medicines Agency algorithm for GPA, were included in this study. They were reclassified based on the 2022 ACR/EULAR criteria. RESULTS: Of the 65 patients, 48 patients (73.8%) were reclassified as having GPA. A patient could not be reclassified as having GPA if the patient did not have a total score of 5 despite granulomas on biopsy or clear GPA surrogate markers. Among the 17 patients unclassified as having GPA, 16 patients were reclassified as having MPA and one as having unclassifiable vasculitis, and furthermore, 94.1% of them harboured MPO-ANCA (or perinuclear (P)-ANCA). CONCLUSION: The concordance rate between the 2022 ACR/EULAR criteria for GPA and the previous criteria in patients with previously diagnosed GPA was 73.8%. Although the 2022 ACR/EULAR criteria are the product of the most advanced methodologic process, it should be noted that there were some consequences of distorting the CHCC definition, and further discussion is required, especially with respect to the weightage of the items.
引用
- Pyo JY, Ahn SS, Song JJ, et al. Reclassification of previously diagnosed GPA patients using the 2022 ACR/EULAR classification criteria. Rheumatology (Oxford). 2023. PMID: 35512176. doi:10.1093/rheumatology/keac267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。